Abstract 1863
Background
The waiting time for cancer diagnosis and treatment could influence patients’ survival. However, in Poland the waiting time is still long. In Poland, medical care is financed by the government and free for patients, but in a situation of long waiting times for diagnostic tests or in cases where it is impossible to obtain some other health services, patients use the private sector. The rationale for this study was to figure out if there are any difficulties in the oncological system and assessment of whether patients have to use the private sector.
Methods
The study was carried out on a group of 384 patients who were being treated for malignant neoplasm in five oncological centers in Poland. A questionnaire was prepared specifically for this study and each patient was interviewed individually. The questionnaire was validated on a group of 20 patients. The measure of compliance was calculated using Cohen’s Kappa coefficient. The study protocol was approved by the Local Ethics Committee. All of the participants had submitted a signed consent form.
Results
202 women and 180 men (2 no data) were analyzed, median age 65 years. 67% of patients declared problems with getting social service and significant differences in getting social service were observed between various regions of Poland (p < 0.001). One third of patients (32%) used private services during the diagnostic process. Patients with higher education showed significantly more frequent problems (p = 0.03). 91% of patients declared difficulties during treatment. Those who showed significantly more frequent problems were: women (p = 0.04), younger patients (p = 0.0015), professionally active (p = 0.025) with higher education (p < 0.001), living in cities (p = 0.016). More than half of patients with higher education (54%) paid for healthcare services in comparison with patients with lower education levels (average 25%) (p < 0.001).
Conclusions
Cancer patients have some difficulties in the oncological system in Poland. The younger people, those with higher education, the professionally active, and those living in cities seem to be more aware of their rights. The proper solution could be to introduce corrections in oncological organization to avoid the need of using private services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract